Upon cell binding, M-Gef-CD133 induced enhanced cytotoxicity compared with non-targeted M-Gef and gefitinib in CD133+ lung CSCs, but not in CD133− lung cancer cells. This evidence concerns the gene PROM1 and lung carcinoma.